An analysis of the National Vaccine Injury Compensation Program's 1986 statutory origins, its administrative framework, and the ongoing institutional debates regarding its function.
When a parent suspects their child was harmed by a vaccine, they cannot sue the pharmaceutical company that made it. They cannot sue in state or federal court.[1] They must instead navigate a unique federal administrative forum formally housed within the U.S. Court of Federal Claims[2] — a system popularly known as "Vaccine Court." The term is an informal shorthand for a specialized administrative process.
This explainer examines the structural design of the National Vaccine Injury Compensation Program (VICP), the legal principles behind it, how it operates in practice, and the serious criticisms it has attracted from both petitioner advocates and public health defenders. We present documented facts and genuine ongoing debate — and distinguish between the two throughout.
The VICP did not emerge primarily from a desire to protect vaccine manufacturers at the expense of injured citizens. It emerged from a genuine supply crisis. By the mid-1980s, the Institute of Medicine (IOM) documented that the cost of the DPT vaccine rose significantly, with manufacturers and the Congressional Research Service citing anticipated litigation costs as a primary driver for the market exit of several U.S. producers.[3] The one remaining major manufacturer threatened to stop production.
The 1976 Swine Flu immunization program had already demonstrated how federal vaccine liability could collapse. Congress vaccinated over 40 million Americans in three months, then watched as approximately $3.5 billion in administrative claims were filed; however, total federal payouts were documented at approximately $90 million across roughly 4,000 resolved claims.[3] That fiasco and the DPT crisis generated the legislative pressure that produced the National Childhood Vaccine Injury Act (NCVIA) of 1986,[1] operational by October 1, 1988.
The legislative record is explicit: Congress intended the VICP to be a non-adversarial, no-fault, swift compensation forum.[1] Senator Edward Kennedy stated that "when children are the victims of an appropriate and rational national policy, a compassionate government will assist them in their hour of need." Congress specified that doubts about causation should be resolved in favor of the petitioner, and that the average time to adjudicate a claim should be approximately 240 days.[3]
In exchange, vaccine manufacturers received broad immunity from product liability lawsuits. Petitioners must exhaust the VICP process before any civil action can be filed.[1]
The term "Vaccine Court" is not a formal legal title. Formally, the Office of Special Masters (OSM) is a division within the U.S. Court of Federal Claims.[2] In almost every structural respect, proceedings before the OSM differ fundamentally from what the American legal tradition recognizes as a court of law.
| Feature | Standard Civil Court | "Vaccine Court" (OSM/VICP) |
|---|---|---|
| Judge or jury | ✔ Judge + optional jury | ✘ Special Master only[2] |
| Manufacturer as defendant | ✔ Named defendant | ✘ Not a party — HHS Secretary is respondent[1] |
| Discovery / depositions | ✔ Standard discovery rights | ✘ Largely unavailable[3] |
| Federal Rules of Evidence | ✔ Strictly applied | ✘ Suspended; Special Masters have wide discretion[1] |
| Federal Rules of Civil Procedure | ✔ Applied | ✘ Suspended[1] |
| Punitive damages | ✔ Permitted | ✘ Expressly prohibited[1] |
| Who pays compensation | Defendant manufacturer | Vaccine Injury Trust Fund (excise tax)[7] |
| Government's role | Neutral arbiter | Active adversary — DOJ defends HHS Secretary[3] |
The practical consequence of this design is that injured petitioners are not suing the entity that made or administered the vaccine. They are filing a petition against the Secretary of Health and Human Services[1] — the same department that approves vaccines, mandates their use, promotes their administration, and manages the trust fund from which any award would be paid. The Department of Justice, representing HHS, opposes most contested claims.[3]
At the heart of the VICP's adjudicatory structure are Special Masters — legal officials, not judges — appointed by the judges of the U.S. Court of Federal Claims. The statutory framework (42 U.S.C. § 300aa-12) limits the OSM to a maximum of eight Special Masters, each serving initial four-year terms.[1][3]
The independence of Special Masters is one of the most actively contested structural questions in VICP discourse — the kind of genuine debate this site's tiered-evidence framework is designed to present without false resolution.
As of the March 2026 HRSA data report,[4] the lifetime record shows 12,848 petitions compensated and 13,222 dismissed out of 26,070 total adjudicated — a dismissal rate of approximately 51 percent. However, this figure is substantially influenced by the Omnibus Autism Proceeding (2002–2010), in which over 5,000 autism-related petitions were consolidated and ultimately dismissed. For petitions filed since January 2006, the compensation rate is approximately 74 percent (10,556 compensated out of 14,325 adjudicated).[4]
The VICP is funded by a $0.75 excise tax on every antigen component of a covered vaccine[8] — meaning the MMR vaccine, protecting against three diseases, carries a $2.25 tax per dose. This revenue flows into the Vaccine Injury Compensation Trust Fund, managed by the U.S. Treasury.[7]
Total outlays since 1988[4]
Current trust fund balance[10]
Petitions filed since 1988[4]
Most public descriptions of the program stop at the $0.75 figure. What they do not explain is what happens to that $0.75 between collection and deposit.
Under 26 U.S.C. § 9510,[7] the Trust Fund does not receive the full $0.75. It receives what the statute defines as "net revenues." When vaccine manufacturers pay the $0.75 excise tax, they deduct it as a business expense on their corporate income taxes — which means the federal government collects less in income tax revenue. Congress accounted for this in the 1987 Omnibus Budget Reconciliation Act (OBRA '87) by directing Treasury to reduce the Trust Fund transfer by 25 percent.[9]
Sources: 26 U.S.C. § 9510(b)(2);[7] Treasury Vaccine Trust Fund Report;[9] GAO Report HEHS-00-8.[6]
Per antigen, per dose — verified against Treasury, GAO, IRS, and HHS FY 2026 Budget
Manufacturers bear zero net cost — they pass through the tax in pricing and deduct it from income taxes
That $0.56 does not go directly to injured families. Congress appropriates money from the Trust Fund each year to pay the operational costs of three federal agencies.[3] As of the HHS FY 2026 Budget Request, the total administrative appropriation from the Trust Fund is $15 million.[10] While recent budget justifications do not provide a granular three-agency breakdown, historical data from the Government Accountability Office establishes the proportional distribution.[5]
| Agency | Role | Historical Share[5] | Est. FY 2026[10] |
|---|---|---|---|
| HRSA (HHS) | Program administration, medical reviews, expert witnesses | ~50% | ~$7.5M |
| DOJ (Torts Branch) | Attorneys who oppose petitioners' claims in court | ~29% | ~$4.4M |
| USCFC / Office of Special Masters | Special Masters, clerks, court operations | ~21% | ~$3.1M |
| Total | 100% | $15.0M |
Sources: HHS FY 2026 Budget Request;[10] GAO-15-142 (agency-level proportions);[5] 26 U.S.C. § 9510.[7] Note: DOJ also incurs expert witness costs from a separate appropriation not billed to the Trust Fund.[6]
In practical terms: the families who pay the excise tax fund not only the compensation awards but also the salaries of the government attorneys who argue against their claims.[5][6]
The $0.75 excise tax is legally imposed on vaccine manufacturers[8] — but the economic burden does not rest with them. Like most manufacturer excise taxes, the cost is embedded in the price of the vaccine and passed through to purchasers: hospitals, pharmacies, insurers, and government programs. Insurers recoup the cost through premiums paid by families and employers. Government purchasing programs — including the CDC's Vaccines for Children (VFC) program, which supplies approximately half of all childhood vaccines in the United States[13] — are funded by taxpayers.
Manufacturers, in turn, deduct the excise tax as an ordinary business expense, reducing their corporate income tax liability. This deduction is the reason Treasury retains 25 percent of gross excise tax receipts before transferring the remainder to the Trust Fund.[7][9]
The practical result is that the Vaccine Injury Compensation Trust Fund is financed almost entirely by the families, employers, and taxpayers who purchase and receive vaccines — not by the manufacturers who produce them. When a family files a petition alleging their child was injured by a vaccine, they are seeking compensation from a fund they themselves helped finance, while the manufacturer whose product is alleged to have caused the injury is not a party to the proceedings and bears no financial responsibility for the outcome.[1] This structure reflects Congress's decision to centralize liability risk while maintaining vaccine supply stability.[3]
Any person — regardless of citizenship — who believes they were injured by a covered vaccine may file a petition.[17] Claims must generally be filed within three years of the first symptom; if the petitioner has died, within two years of death and four years of first symptoms.[1]
DVIC within HRSA reviews the claim and produces a medical analysis report forwarded to DOJ. HRSA is a component of HHS.[3]
DOJ attorneys, representing the HHS Secretary, review HRSA's report and issue a legal position on whether compensation is warranted. This is the formal adversarial stage.[3]
Approximately 60 percent of compensated claims resolve via negotiated settlement — without HHS formally concluding the vaccine caused the injury.[12]
Petitioners who disagree with the judgment may reject it and pursue civil litigation. However, Bruesewitz v. Wyeth Labs (2011) eliminated design-defect claims, severely limiting the civil tort option.[18]
In practice, claims regularly take far longer than Congress intended. Congressional testimony from 2024 documented typical wait times of 18–24 months just to reach a trial date — after up to 16 months of initial HRSA review.[15] Claims involving off-table injuries routinely take five or more years; some exceed ten.[5] On average, it takes 2 to 3 years to adjudicate a petition after it is filed.[4]
The Vaccine Injury Table (VIT), maintained by the HHS Secretary, lists specific vaccines and associated injuries presumed to be causally connected.[1] "On-table" claims — where the injury and onset window match — are presumed to be caused by the vaccine. "Off-table" claims require the petitioner to independently prove causation by a preponderance of evidence.[3] Attorneys practicing in the program estimate that today, up to 90 percent of non-dismissed petitions involve off-table claims.[14]
The U.S. Government Accountability Office documented in its 2014 report[5] that between 1999 and 2014, HHS had added six vaccines to the VIT without adding any corresponding covered injuries, effectively making all claims for those products "off-table." While the March 21, 2017, VIT revision addressed some of these gaps by adding injuries such as Guillain-Barré Syndrome (GBS) for seasonal flu vaccines and Shoulder Injury Related to Vaccine Administration (SIRVA) for several others,[19] the practice of adding new vaccines to the program without immediate injury-presumption status remains a point of institutional scrutiny.
The HHS Secretary holds largely unchecked authority to modify the table.[1] Barbara Loe Fisher, a prominent parent advocate who participated in the NCVIA legislative process, testified to Congress in 1999 that the principal reason the program had become adversarial was that the Secretary had exercised rulemaking authority to unilaterally change the table in ways that dramatically reduced the number of injuries covered.[6]
The Vaccine Safety Datalink (VSD) is a CDC-maintained database linking vaccination records and medical outcomes across millions of Americans. Petitioners in the VICP are consistently denied access to VSD data for use in proving causation.[14]
Petitioner advocates argue that this effectively withholds the government's best epidemiological evidence from the individuals the program is meant to serve, while government attorneys can internally reference the database in building their defense position.[14]
The CDC maintains that restrictions are necessary to protect the proprietary nature of healthcare partner data and the privacy of the millions of individuals whose records are linked within the system. CDC also notes that VSD findings are regularly published in peer-reviewed studies accessible to all parties.
HRSA's own published statistics confirm (as of March 2026) that approximately 60 percent of all VICP compensation comes through negotiated settlement — and that in those settlements, "HHS has not concluded, based upon review of the evidence, that the alleged vaccine(s) caused the alleged injury."[12]
This means that a substantial majority of compensated families receive no official acknowledgment that the vaccine caused their child's injury. It also means that aggregate VICP statistics — routinely cited in public communications — do not reliably indicate how many injuries were officially determined to be vaccine-caused versus how many were resolved to avoid litigation cost, delay, or risk.[12][5]
As of early 2026, advocates and a bipartisan coalition in Congress continue to push for VICP modernization legislation modeled after the 2023 H.R. 5142 proposal.[11] Its core provisions — including increasing the number of Special Masters, updating the death benefit cap (unchanged at $250,000 since 1986[1]), and streamlining the initial HRSA review process — remain the primary framework for active reform discussions.
In July 2025, HHS Secretary Robert F. Kennedy Jr. issued a public statement describing the VICP as a "morass of inefficiency, favoritism, and outright corruption." FactCheck.org noted that while Kennedy's structural critiques had factual basis, he omitted certain petitioner-friendly features of the VICP relative to the civil tort alternative.[16]
The National Childhood Vaccine Injury Act was designed — in name and in statute — to compensate children injured by childhood vaccines. Every element of the program's naming and statutory structure reflects this origin: the law is called the "National Childhood Vaccine Injury Act";[1] the excise tax under 26 U.S.C. § 4131 applies to vaccines "recommended by the CDC for routine administration to children";[8] and the advisory body is called the "Advisory Commission on Childhood Vaccines."[1] The legislative history is unambiguous — Congress created this program to protect children.[3]
The program's evolution has produced a demographic outcome Congress did not foresee. As ACIP expanded the list of covered vaccines — particularly with the addition of influenza vaccine to the Vaccine Injury Table in 2005 — the VICP began covering vaccines administered primarily to adults. The single largest category of VICP claims is now Shoulder Injury Related to Vaccine Administration (SIRVA), an injury caused by improper injection technique rather than an adverse reaction to vaccine components. SIRVA was formally added to the Vaccine Injury Table in 2017[19] and accounts for more than half of all claims filed.[19]
According to the March 2026 HRSA data report, influenza-related petitions account for 11,687 of the 29,670 total petitions filed since 1988 — approximately 39 percent.[4] HRSA itself acknowledges in its data report footnote: "Since influenza vaccines (vaccines administered to large numbers of adults each year) were added to the VICP in 2005, many adult petitions related to that vaccine have been filed, thus changing the proportion of children to adults receiving compensation."[4]
This demographic evolution raises questions about the program's scope relative to its original legislative mandate, whether the funding mechanism — an excise tax justified by childhood vaccination policy[8] — is being used as Congress intended, and whether the Trust Fund should primarily compensate adults for injection-technique errors.
| Dimension | VICP (Childhood Vaccines)[1] | CICP (Countermeasures)[17] |
|---|---|---|
| Covered products | Vaccines recommended for routine pediatric/adolescent use (on the VIT) | Countermeasures under PREP Act declarations (e.g., EUA products) |
| Filing deadline | 3 years from first symptom | 1 year from administration |
| Standard of proof | Preponderance of evidence | Compelling, reliable, valid medical and scientific evidence |
| Attorney fees | Covered regardless of outcome | Not covered |
| Compensation cap | No aggregate cap (death capped at $250K) | Strictly capped; no pain & suffering |
| Right to appeal | To U.S. Court of Federal Claims | Administrative only; no judicial review |
The January 2026 transition to a three-tier federal schedule has introduced a new layer of legal inquiry regarding program eligibility. Under 42 U.S.C. § 300aa-11,[1] the VICP's statutory "trigger" requires that a vaccine be "recommended for routine administration" by the CDC.
Under the 2026 framework, vaccines in Tier 3 — such as Influenza and COVID-19 — are still recommended by the CDC; however, that recommendation is now channeled through shared clinical decision-making rather than a universal default. As of early 2026, HRSA has not issued a formal rule change to the VIT regarding this update. The current judicial understanding is that as long as a vaccine remains on the VIT and is recommended for any routine pediatric sub-population, it satisfies the statutory requirement for VICP jurisdiction. This remains an evolving area of law, and future administrative or judicial rulings may further refine how "routine administration" is defined in this context.
Every factual claim in this article carries an inline citation number linking to its source below. All statistics are drawn from official government data — HRSA, GAO, CRS, Treasury — unless otherwise noted. Advocacy sources are explicitly labeled. This article does not represent the official position of any government agency, pharmaceutical company, or advocacy organization.